Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Fresenius Medical Care AG & Co. KGaA    FME   DE0005785802

FRESENIUS MEDICAL CARE AG & CO. KGAA

(FME)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Fresenius forecasts 2020 profit growth driven by drug, dialysis units

share with twitter share with LinkedIn share with facebook
share via e-mail
02/20/2020 | 01:26pm EDT
FILE PHOTO: Fresenius headquarters in in Bad Homburg

German healthcare group Fresenius said it expects net income to increase in 2020 after strong growth in its dialysis business, and in its infusion drugs unit in emerging markets, helped it to just beat fourth quarter expectations.

Following a tumultuous 2018 when Fresenius issued several profit warnings, last year was marked by investment and stabilisation, with the group's management pointing to an improvement from 2020 onwards.

Separately-listed dialysis unit Fresenius Medical Care, which generated 49% of the group's quarterly revenue, on Wednesday reported in-line results saying record growth in home care dialysis offset the one-off effects of an ongoing legal dispute.

Home care has been a growth area for the world's largest kidney dialysis provider, but it has been critical of hard targets set by President Donald Trump's administration for treating more patients with kidney disease at home.

While the company is confident the administration will soften its initial goals in this area, FMC expects home dialysis to account for between 25% and 30% of treatments in the U.S. by 2025, up from 13% now, Chief Executive Rice Powell told Reuters.

Despite some softness in North America, group fourth-quarter adjusted operating income came in at 1.29 billion euros (1.08 billion pounds), slightly above the 1.25 billion euros expected on average by analysts in a company-provided consensus.

Fresenius said it expected 2020 net income to rise between 1% and 5% in constant currency terms and confirmed mid-term forecasts, saying growth, efficiency improvements and its biosimilars business should all bolster earnings.

It said it was too early to quantify the impact of the coronavirus outbreak in China, which has killed 2,100 and infected 74,000 while disrupting the global economy.

Chief Executive Stephan Sturm told a news conference the infusion drugs division Kabi was the most exposed, but the effect would likely not be significant for the unit or group.

In a separate statement, Fresenius announced a joint venture between Kabi and Swiss rival Vifor Pharma to provide iron deficiency treatments in China.

The group's Helios hospital division, which has continued to stabilise in Germany and grow in Spain, will keep looking for opportunities to expand this year after making several acquisitions in Colombia, Sturm said.

Fresenius shares closed 2.3% higher while FMC ended the day up 3.7%.

By Zuzanna Szymanska

Stocks mentioned in the article
ChangeLast1st jan.
FRESENIUS MEDICAL CARE AG & CO. KGAA 1.64% 63.24 Delayed Quote.-4.12%
FRESENIUS SE & CO. KGAA 0.48% 38.01 Delayed Quote.-24.25%
ROUGH RICE FUTURES (ZR) - CBE (ELECTRONIC)/C1 1.40% 14.515 End-of-day quote.9.17%
VIFOR PHARMA 1.42% 143 Delayed Quote.-19.05%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on FRESENIUS MEDICAL CARE AG
04/09FMC FRESENIUS MEDICAL CARE AG & CO K : Receives a Buy rating from Goldman Sachs
MD
04/09FRESENIUS MEDICAL CARE : calls for kidney disease patients to have continued acc..
PU
04/03FRESENIUS MEDICAL CARE AG & CO. KGAA : Release according to Article 40, Section ..
EQ
04/03FRESENIUS MEDICAL CARE AG & CO. KGAA : Release of a capital market information
EQ
04/01FRESENIUS MEDICAL CARE AG & CO. KGAA : Release according to Article 40, Section ..
EQ
04/01FRESENIUS MEDICAL CARE : partners with other dialysis providers to combat corona..
EQ
03/31FRESENIUS MEDICAL CARE AG & CO. KGAA : Release according to Article 41 of the Wp..
EQ
03/30FRESENIUS MEDICAL CARE AG & CO. KGAA : Release of a capital market information
EQ
03/30FRESENIUS MEDICAL CARE AG & CO. KGAA : Publication of acquisition or disposal in..
EQ
03/30FRESENIUS MEDICAL CARE : postpones 2020 Annual General Meeting
EQ
More news
Financials (USD)
Sales 2020 20 361 M
EBIT 2020 2 688 M
Net income 2020 1 407 M
Debt 2020 13 809 M
Yield 2020 1,95%
P/E ratio 2020 14,6x
P/E ratio 2021 12,5x
EV / Sales2020 1,67x
EV / Sales2021 1,48x
Capitalization 20 219 M
Chart FRESENIUS MEDICAL CARE AG & CO. KGAA
Duration : Period :
Fresenius Medical Care AG & Co. KGaA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends FRESENIUS MEDICAL CARE AG
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 85,94  $
Last Close Price 69,09  $
Spread / Highest target 56,2%
Spread / Average Target 24,4%
Spread / Lowest Target -31,5%
EPS Revisions
Managers
NameTitle
Rice Powell Chairman-Management Board
Dieter Schenk Chairman-Supervisory Board
Helen Giza Chief Financial Officer
Olaf Schermeier CEO-Global Research & Development
Franklin W. Maddux Global Chief Medical Officer
Sector and Competitors